



**Department of Vermont Health Access
Pharmacy Benefits Management Program
*DUR Board Meeting Agenda***

****Please note date****

April 10, 2012 6:30 – 9:00 p.m.

- 1. Executive Session** **6:30 - 7:00**
 - Discussion on Medicaid OBRA'90/Supplemental Rebates and Agreements (as provided by 33 VSA § 1998(f)(2))

- 2. Introductions and Approval of DUR Board Minutes** **7:00 - 7:05**

(Public Comment Prior to Board Action)

- 3. DVHA Pharmacy Administration Updates** **7:05 - 7:15**
 - Medications to be Dispensed as Initial 15 Day Supply

- 4. Medical Director Update** **7:15 - 7:20**
 - Clinical Programs Update
 - Prescriber Comments

- 5. Follow-up Items from Previous Meetings** **7:20 - 7:25**
 - Citalopram > 40 mg/day (new FDA update)

- 6. RetroDUR/DUR** **7:25 - 7:55**
 - Narcotic Analgesics – Short Acting
 - Psychotropic Medication Use in Children SFY 2009 – 2011
 - Psychotropic Medication Use in Children in Foster Care SFY 2009 - 2011

- 7. Clinical Update: Drug Reviews** **7:55 – 8:30**

(Public comment prior to Board action)

Abbreviated Drug Reviews

 - Conzip[®] (tramadol extended release) Capsule
 - Gralise[®] (gabapentin) Tablet
 - Juvisync[®] (sitagliptin/simvastatin) Tablet
 - Orencia[®] (abatacept) Subcutaneous Injection

Full New Drug Reviews

 - Onfi[®] (clobazam) Tablet
 - Firazyr[®] (icatibant) Prefilled Syringe for Subcutaneous Injection
 - Solesta[®] Gel Prefilled Syringe for Submucosal Injection

- 8. Therapeutic Drug Classes – Periodic Review** **8:30 – 8:40**
(Public comment prior to Board action)
Class review documents available on DVHA web site 4/10/2012 @ 12 Noon
- Anti-Fungals – Oral
 - Anti-Diabetics – Oral - Thiazolidinediones
 - Insulins
 - Osteoporosis Treatments
- 9. New Managed Therapeutic Drug Classes** **8:40 – 8:45**
(Public comment prior to Board action)
- Antihypertensives: Alpha Blockers
- 10. Review of Newly-Developed/Revised Clinical Coverage Criteria and/or Preferred Products** **8:45 – 8:45**
(Public comment prior to Board action)
- None
- 11. General Announcements** **8:45– 8:55**
Selected FDA Safety Alerts
- Proton Pump Inhibitors – Drug Safety Communication – Clostridium difficile associated diarrhea
 - Statins and Protease Inhibitors – Risk of Muscle Injury
 - Statins – Labelling Changes
 - Tysabri[®] - Drug Safety Communication – Update of Risk Factors for PML
 - Victrelis[®] - Drug Safety Communication – Important Drug Interaction with Certain HIV Protease Inhibitors
- 12. Adjourn** **9:00**